Lower β2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia

American Journal of Psychiatry

Volumn 169, Issue 3, 2012, Pages 326-334

  D'Souza, Deepak Cyril ^a,b,c,d   Esterlis, Irina ^a,b,c,d   Carbuto, Michelle ^a,b,c,d   Krasenics, Maegan ^a,b,c,d   Seibyl, John ^a,b,c,d   Bois, Frederic ^a,b,c,d   Pittman, Brian ^a,b,c,d   Ranganathan, Mohini ^a,b,c,d   Cosgrove, Kelly ^a,b,c,d   Staley, Julie ^a,b,c,d  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; IODINE 123; NICOTINIC RECEPTOR BETA2; OLANZAPINE; RISPERIDONE; NICOTINIC RECEPTOR;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; CEREBELLUM; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; MALE; MORNING DOSAGE; NEGATIVE SYNDROME; OCCIPITAL CORTEX; PARIETAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING CESSATION; TEMPORAL CORTEX; THALAMUS; BRAIN LEVEL; CHEMISTRY; FEMALE; FRONTAL LOBE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SMOKING;

ADULT; BRAIN CHEMISTRY; FEMALE; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARIETAL LOBE; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84858984602     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11020189     Document Type: Article

References (48)

1. Dalack GW, Healy DJ, Meador-Woodruff JH: Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998; 155:1490-1501 (Pubitemid 28512015)
2. de Leon J, Diaz FJ: A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76:135-157
3. Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW: Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 1998; 33:113-118 (Pubitemid 28439252)
4. de Leon J, Becona E, Gurpegui M, Gonzalez-Pinto A, Diaz FJ: The association between high nicotine dependence and severe mental illness may be consistent across countries. J Clin Psychiatry 2002; 63:812-816
5. Kelly C, McCreadie RG: Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999; 156:1751-1757 (Pubitemid 29517568)
6. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP: Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998; 391:173-177 (Pubitemid 28092475)
7. Breese C, Marks M, Logel J, Adams C, Sullivan B, Collins A, Leonard S: Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 1997; 282:7-13 (Pubitemid 27425521)
8. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, Collins AC: Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci 1992; 12:2765-2784
9. Flores C, Rogers S, Pabreza L, Wolfe B, Kellar K: A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 1992; 41:31-37
10. Schwartz R, Kellar K: Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 1983; 220:214-216 (Pubitemid 13115272)
11. Cosgrove KP, Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski T, Stiklus S, Krishnan-Sarin S, O'Malley S, Perry E, Tamagnan G, Seibyl JP, Staley JK: Beta2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry 2009; 66:666-676
12. Moroni M, Zwart R, Sher E, Cassels BK, Bermudez I: Alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to longterm exposure to nicotine. Mol Pharmacol 2006; 70:755-768 (Pubitemid 44092336)
13. Kuryatov A, Onksen J, Lindstrom J: Roles of accessory subunits in alpha4beta2(*) nicotinic receptors. Mol Pharmacol 2008; 74:132-143 (Pubitemid 351872165)
14. Marks MJ, McClure-Begley TD, Whiteaker P, Salminen O, Brown RW, Cooper J, Collins AC, Lindstrom JM: Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. J Pharmacol Exp Ther 2011; 337:187-200
15. Breese C, Lee M, Adams C, Sullivan B, Logel J, Gillen K, Marks M, Collins A, Leonard S: Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000; 23:351-364
16. Durany N, Zochling R, Boissl K, Paulus W, Ransmayr G, Tatschner T, Danielczyk W, Jellinger K, Deckert J, Riederer P: Human postmortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000; 287:109-112 (Pubitemid 30353059)
17. Voineskos S, De Luca V, Mensah A, Vincent JB, Potapova N, Kennedy JL: Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia. J Psychiatry Neurosci 2007; 32:412-416 (Pubitemid 350248227)
18. Esterlis I, Cosgrove KP, Batis JC, Bois F, Stiklus SM, Perkins E, Seibyl JP, Carson RE, Staley JK: Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med 2010; 51:1226-1233
19. 123I]iodo-A-85380 using single photon emission computed tomography. Life Sci 1998; 63(25):PL355-PL360
20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO: The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addiction 1991; 86:1119-1127
21. Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin JA, Estok K, Brenner E, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, Picciotto MR, London ED, O'Malley S, van Dyck CH: Human tobacco smokers in early abstinence have higher levels of beta2*nicotinic acetylcholine receptors than nonsmokers. J Neurosci 2006; 26:8707-8714 (Pubitemid 44319406)
22. Tiffany S, Drobes D: The development and initial validation of a questionnaire on smoking urges. Br J Addiction 1991; 86:1467-1476
23. Hatsukami DK, Hughes JR, Pickens RW, Svikis D: Tobacco withdrawal symptoms: an experimental analysis. Psychopharmacology (Berl) 1984; 84:231-236 (Pubitemid 14006578)
24. Kay SR, Opler LA, Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989; 7:59-67
25. Andreasen NC: The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 1989; 7:49-58
26. Montgomery SM: Depressive symptoms in acute schizophrenia. Prog Neuropsychopharmacol 1979; 3:429-433
27. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
28. Zoghbi S, Tamagnan G, Fujita M, Baldwin RM, Amici L, Tikriti MA, Seibyl J, Innis R: Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2- azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nucl Med Biol 2001; 28:91-96 (Pubitemid 32155969)
29. Wonnacott S: The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 1990; 11:216-219
30. Cosgrove K, Mitsis E, Bois F, Frohlich E, Tamagnan G, Krantzler E, Perry E, Maciejewski P, Epperson C, Allen S, O'Malley S, Mazure C, Seibyl J, van Dyck CH, Staley J: 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. J Nucl Med 2007; 48:1633-1640 (Pubitemid 47572711)
31. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J Nucl Med 2005; 46:1466-1472
32. Dani JA, Heinemann S: Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16:905-908 (Pubitemid 26171196)
33. Sharp BM, Beyer HS: Rapid desensitization of the acute stimulatory effects of nicotine on rat plasma adrenocorticotropin and prolactin. J Pharmacol Exp Ther 1986; 238:486-491 (Pubitemid 16039585)
34. 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006; 63:907-915
35. De Luca V, Voineskos S, Wong G, Kennedy JL: Genetic interaction between alpha4 and beta2 subunits of high affinity nicotinic receptor: analysis in schizophrenia. Exp Brain Res 2006; 174:292-296 (Pubitemid 44421106)
36. Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Inada T, Ozaki N, Iwata N: Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population. J Neural Transm 2008; 115:1457-1461
37. Faraone SV, Su J, Taylor L, Wilcox M, Van Eerdewegh P, Tsuang MT: A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families. Hum Hered 2004; 57:59-68 (Pubitemid 38798148)
38. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ: Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994; 45:204-206 (Pubitemid 24079650)
39. Ucok A, Polat A, Bozkurt O, Meteris H: Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 2004; 58:434-437 (Pubitemid 39108547)
40. Patkar AA, Gopalakrishnan R, Lundy A, Leone FT, Certa KM, Weinstein SP: Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. J Nerv Ment Dis 2002; 190:604-610
41. Taiminen TJ, Salokangas RK, Saarijarvi S, Niemi H, Lehto H, Ahola V, Syvalahti E: Smoking and cognitive deficits in schizophrenia: a pilot study. Addict Behav 1998; 23:263-266 (Pubitemid 28136015)
42. Smith RC, Singh A, Infante M, Khandat A, Kloos A: Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002; 27:479-497 (Pubitemid 35253795)
43. Grenhoff J, Aston-Jones G, Svensson TH: Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 1986; 128:351-358 (Pubitemid 17182735)
44. Di Chiara G: Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000; 393:295-314
45. Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR: Nicotine-induced dopamine release in primates measured with [C-11]raclopride PET. Neuropsychopharmacology 2004; 29:259-268 (Pubitemid 38175145)
46. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486
47. Terry AV Jr, Gearhart DA, Mahadik SP, Warsi S, Waller JL: Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. Neuroscience 2006; 140:1277-1287 (Pubitemid 43928280)
48. Fujita M, Al-Tikriti MS, Tamagnan G, Zoghbi SS, Bozkurt A, Baldwin RM, Innis RB: Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380. Synapse 2003; 48:116-122 (Pubitemid 36444336)